인플루엔자 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Influenza Vaccine Market size is expected to reach USD 17.88 Billion in 2034 from USD 9.58 Billion (2025) growing at a CAGR of 7.18% during 2026-2034.

The Global Influenza Vaccine Market is witnessing consistent growth due to increasing awareness about seasonal flu prevention. Governments and health organizations worldwide conduct annual vaccination campaigns to reduce flu-related hospitalizations and deaths. Rising cases of influenza outbreaks and the risk of pandemics are pushing healthcare systems to strengthen immunization programs. Technological advancements in vaccine development, including cell-based and recombinant vaccines, are also supporting market expansion.

One of the main drivers is the growing emphasis on preventive healthcare and immunization coverage. High-risk groups such as elderly individuals, children, and patients with chronic diseases require regular flu vaccination. Government funding, public health initiatives, and improved cold chain infrastructure are enhancing vaccine distribution. Additionally, pharmaceutical companies are investing in research and development to improve vaccine effectiveness and production capacity.

In the coming years, the market is expected to grow steadily with improved global vaccination rates. Expanding healthcare access in emerging economies will create new growth opportunities. Innovations in universal flu vaccines and faster production methods may further strengthen the industry. As global health preparedness becomes a priority, the influenza vaccine market is likely to maintain stable and long-term growth worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Inactivated
• Live Attenuated

By Indication

• Quadrivalent
• Trivalent

By Age Group

• Pediatric
• Adult

By Route of Administration

• Injection
• Nasal Spray

By Distribution Channel

• Hospitals & Pharmacies
• Government & Institutional Supply
• Others

COMPANIES PROFILED

• GSK plc, Pfizer Inc, Vaxess Technologies Inc, Merck Co Inc, Viatris Inc, Osivax, AstraZeneca plc, Sinovac Biotech Ltd, CSL Limited, Emergent BioSolutions Inc, Emergex Vaccines Holding Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFLUENZA VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL INFLUENZA VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Trivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL INFLUENZA VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL INFLUENZA VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Nasal Spray Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL INFLUENZA VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospitals & Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Government & Institutional Supply Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL INFLUENZA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.2.1 By Vaccine Type
  • 9.2.2 By Indication
  • 9.2.3 By Age Group
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.3.1 By Vaccine Type
  • 9.3.2 By Indication
  • 9.3.3 By Age Group
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.4.1 By Vaccine Type
  • 9.4.2 By Indication
  • 9.4.3 By Age Group
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.5.1 By Vaccine Type
  • 9.5.2 By Indication
  • 9.5.3 By Age Group
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.6.1 By Vaccine Type
  • 9.6.2 By Indication
  • 9.6.3 By Age Group
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INFLUENZA VACCINE INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 GSK Plc
  • 11.2.2 Pfizer Inc
  • 11.2.3 Vaxess Technologies Inc
  • 11.2.4 Merck & Co. Inc
  • 11.2.5 Viatris Inc
  • 11.2.6 Osivax
  • 11.2.7 AstraZeneca Plc
  • 11.2.8 Sinovac Biotech Ltd
  • 11.2.9 CSL Limited
  • 11.2.10 Emergent BioSolutions Inc
  • 11.2.11 Emergex Vaccines Holding Ltd